Sanaria procures US grant for malaria research
This article was originally published in Scrip
Sanaria, a private company based in Rockville, Maryland, and the University of Maryland Biotechnology Institute have been awarded a $600,000 phase 1 small business innovation research (SBIR) grant from the US National Institute of Allergy and Infectious Diseases to support R&D efforts to genetically engineer mosquitoes that can enhance Sanaria's whole-parasite malaria vaccine production process. Sanaria plans to begin the first human trials of its malaria vaccine in 2009. It claims that its goal is to develop and commercialise a malaria sporozoite vaccine against Plasmodium falciparum.